Skip to main content
. 2019 Oct 15;9:1059. doi: 10.3389/fonc.2019.01059

Figure 1.

Figure 1

Screening pseudogenes used for constructing the risk signature for glioma. Principal components analysis of pseudogenes between glioblastoma (GBM) and low grade glioma (LGG) in the training cohort (A) and the validation cohort (B). (C) Heatmap showed the pseudogenes differentially expressed between LGG and GBM in the training cohort (| log2(fold-change) | ≥ 2 and FDR < 0.05). (D) Log (Lambda) value of the 15 pseudogenes in LASSO model. (E) The most appropriate log (Lambda) value in the LASSO model. (F) Multivariate Cox regression analysis was performed and five pseudogenes (ANXA2P2, EEF1A1P9, FER1L4, HILS1, and RAET1K) were selected to construct the risk signature.